Collaborations are emerging to scale and optimize cell therapy manufacturing. Sartorius Stedim Biotech partnered with Nanotein Technologies to commercialize NanoSpark soluble activators that enhance expansion of T cells and NK cells without feeder constructs, streamlining workflows for cell and gene therapies. These reagents and joint product development efforts aim to improve immune cell yield and quality, addressing bottlenecks in CAR-T and related therapies. Such innovations mark an important advance for industrializing complex cell therapy manufacturing processes.